Neurobiological Financial Statements From 2010 to 2026
| NTII Stock | USD 0.0001 0.00 0.00% |
Check Neurobiological Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurobiological Technologies' main balance sheet or income statement drivers, such as , as well as many indicators such as . Neurobiological financial statements analysis is a perfect complement when working with Neurobiological Technologies Valuation or Volatility modules.
Neurobiological | Build AI portfolio with Neurobiological Stock |
Neurobiological Technologies Company Return On Equity Analysis
Neurobiological Technologies' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Neurobiological Technologies Return On Equity | 1.0 |
Most of Neurobiological Technologies' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurobiological Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Neurobiological Technologies has a Return On Equity of 0.9972. This is 104.16% lower than that of the Biotechnology sector and 102.74% lower than that of the Health Care industry. The return on equity for all United States stocks is notably lower than that of the firm.
Neurobiological Technologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neurobiological Technologies's current stock value. Our valuation model uses many indicators to compare Neurobiological Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neurobiological Technologies competition to find correlations between indicators driving Neurobiological Technologies's intrinsic value. More Info.Neurobiological Technologies is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in profit margin category among its peers fabricating about 0.74 of Profit Margin per Return On Equity. The ratio of Return On Equity to Profit Margin for Neurobiological Technologies is roughly 1.35 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neurobiological Technologies' earnings, one of the primary drivers of an investment's value.About Neurobiological Technologies Financial Statements
Investors use fundamental indicators, such as Neurobiological Technologies' revenue or net income, to determine how well the company is positioned to perform in the future. Although Neurobiological Technologies' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Neurobiological Technologies, Inc. operates under a plan of liquidation and dissolution approved by stockholders in October 2009. The company was founded in 1987 and is based in Emeryville, California. Neurobiological Technologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.
Currently Active Assets on Macroaxis
When determining whether Neurobiological Technologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurobiological Technologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurobiological Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurobiological Technologies Stock:Check out the analysis of Neurobiological Technologies Correlation against competitors. For more detail on how to invest in Neurobiological Stock please use our How to Invest in Neurobiological Technologies guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobiological Technologies. If investors know Neurobiological will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobiological Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurobiological Technologies is measured differently than its book value, which is the value of Neurobiological that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobiological Technologies' value that differs from its market value or its book value, called intrinsic value, which is Neurobiological Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobiological Technologies' market value can be influenced by many factors that don't directly affect Neurobiological Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobiological Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobiological Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobiological Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.